MyPeptideMatchOverview
Hexarelin is a growth hormone secretagogue studied for GH release and, in preclinical work, cardiac protection. It is prohibited for compounding in the US with no pathway. It is not FDA-approved. Evidence is emerging—primarily preclinical and early human studies. For legal GH support, consider sermorelin.
How It Works (Mechanism of Action)
Hexarelin stimulates growth hormone release via the GHSR. Preclinical data suggest possible cardioprotective effects; human data are limited.
Primary Uses
Marketed for GH release. Preclinical interest in cardiac protection. Not legal for compounding.
FDA & Regulatory Status
Prohibited for compounding. No pathway.
Last reviewed February 2026.
Clinical Evidence
Emerging—primarily preclinical and early human studies.
Side Effects & Safety
Limited human data. Not legally available in the US.
What to Expect at a Clinic
Not offered legally. See sermorelin for legal GH options.
Cost & Insurance
Not applicable.
